175 related articles for article (PubMed ID: 35047498)
1. Identification of Breast Cancer Immune Subtypes by Analyzing Bulk Tumor and Single Cell Transcriptomes.
Yao J; Li S; Wang X
Front Cell Dev Biol; 2021; 9():781848. PubMed ID: 35047498
[No Abstract] [Full Text] [Related]
2. Identification of prostate cancer subtypes based on immune signature scores in bulk and single-cell transcriptomes.
Chen C; Luo J; Wang X
Med Oncol; 2022 Jun; 39(9):123. PubMed ID: 35716212
[TBL] [Abstract][Full Text] [Related]
3. Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer.
Xu J; Bao H; Wu X; Wang X; Shao YW; Sun T
Oncol Lett; 2019 Jul; 18(1):449-455. PubMed ID: 31289516
[TBL] [Abstract][Full Text] [Related]
4. Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients.
Tao Z; Li T; Feng Z; Liu C; Shao Y; Zhu M; Gong C; Wang B; Cao J; Wang L; Du Y; Lizaso A; Li B; Zhang J; Hu X
Front Oncol; 2020; 10():1023. PubMed ID: 32695676
[No Abstract] [Full Text] [Related]
5. Classification of triple-negative breast cancer based on pathway enrichment levels.
Liu Q; Wang X
Med Oncol; 2023 Apr; 40(6):157. PubMed ID: 37093316
[TBL] [Abstract][Full Text] [Related]
6. Subtyping of sarcomas based on pathway enrichment scores in bulk and single cell transcriptomes.
Li S; Liu Q; Zhou H; Lu H; Wang X
J Transl Med; 2022 Jan; 20(1):48. PubMed ID: 35093080
[TBL] [Abstract][Full Text] [Related]
7. Subtyping of head and neck squamous cell cancers based on immune signatures.
Song D; Lyu H; Feng Q; Luo J; Li L; Wang X
Int Immunopharmacol; 2021 Oct; 99():108007. PubMed ID: 34332341
[TBL] [Abstract][Full Text] [Related]
8. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
[TBL] [Abstract][Full Text] [Related]
9. Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer: a novel molecular subtyping strategy and immunotherapeutic prediction model.
Zheng K; Hai Y; Chen H; Zhang Y; Hu X; Ni K
J Transl Med; 2024 Apr; 22(1):365. PubMed ID: 38632658
[TBL] [Abstract][Full Text] [Related]
10. Novel immune subtypes identification of HER2-positive breast cancer based on immunogenomic landscape.
Huang L; Liu X; Li L; Wang L; Wu N; Liu Z
Med Oncol; 2022 May; 39(5):92. PubMed ID: 35568771
[TBL] [Abstract][Full Text] [Related]
11. Identification of subtypes correlated with tumor immunity and immunotherapy in cutaneous melanoma.
Liu Q; Nie R; Li M; Li L; Zhou H; Lu H; Wang X
Comput Struct Biotechnol J; 2021; 19():4472-4485. PubMed ID: 34471493
[TBL] [Abstract][Full Text] [Related]
12. Molecular classification of human papillomavirus-positive cervical cancers based on immune signature enrichment.
Song G; Luo J; Zou S; Lou F; Zhang T; Zhu X; Yang J; Wang X
Front Public Health; 2022; 10():979933. PubMed ID: 36203656
[TBL] [Abstract][Full Text] [Related]
13. Classification of lung adenocarcinoma based on stemness scores in bulk and single cell transcriptomes.
Liu Q; Lei J; Zhang X; Wang X
Comput Struct Biotechnol J; 2022; 20():1691-1701. PubMed ID: 35495113
[TBL] [Abstract][Full Text] [Related]
14.
Liu Z; Jiang Z; Gao Y; Wang L; Chen C; Wang X
J Oncol; 2019; 2019():5952836. PubMed ID: 31275382
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
16. Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
Lee S; Kim HY; Jung YJ; Jung CS; Im D; Kim JY; Lee SM; Oh SH
Curr Probl Cancer; 2022 Apr; 46(2):100843. PubMed ID: 35180531
[TBL] [Abstract][Full Text] [Related]
17. Distinct Somatic Alteration Features Identified by Gene Panel Sequencing in Korean Triple-Negative Breast Cancer with High Ki67 Expression.
Sun WY; Lee J; Kim BK; Kim JO; Park J
Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33804295
[TBL] [Abstract][Full Text] [Related]
18. Immune gene expression profiling reveals heterogeneity in luminal breast tumors.
Zhu B; Tse LA; Wang D; Koka H; Zhang T; Abubakar M; Lee P; Wang F; Wu C; Tsang KH; Chan WC; Law SH; Li M; Li W; Wu S; Liu Z; Huang B; Zhang H; Tang E; Kan Z; Lee S; Park YH; Nam SJ; Wang M; Sun X; Jones K; Zhu B; Hutchinson A; Hicks B; Prokunina-Olsson L; Shi J; Garcia-Closas M; Chanock S; Yang XR
Breast Cancer Res; 2019 Dec; 21(1):147. PubMed ID: 31856876
[TBL] [Abstract][Full Text] [Related]
19. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of tumor mutation burden and the relationship between tumor mutation burden and immune infiltration in
Wen Y; Ouyang D; Chen Q; Zeng L; Luo N; He H; Anwar M; Qu L; Zou Q; Yi W
Gland Surg; 2022 Jan; 11(1):100-114. PubMed ID: 35242673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
